management of antibiotic resistant...
TRANSCRIPT
![Page 1: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/1.jpg)
Management of Antibiotic‐Resistant Pathogens
Zach Willis, MD, MPHDepartment of Pediatrics, UNC
11/8/2017
![Page 2: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/2.jpg)
I have no disclosures
![Page 3: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/3.jpg)
Overview
• Introduction– Burden of antibiotic resistance (AR) – focus on inpatient settings– Critical antibiotics – current and under development– Diagnosis
• AR pathogens of epidemiologic significance– Gram‐positive: S. aureus, Enterococcus– Gram‐negative bacilli: ESBL, carbapenem resistance– Fungi: Candida spp
![Page 4: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/4.jpg)
Learning Objectives• Antimicrobial Resistance
– How it develops– How it’s detected– How it spreads
• Specific and emerging antimicrobial resistance problems– Gram‐positive: MRSA, VRE– Gram‐negative: ESBL, carbapenemases, polymyxin resistance– Fungal: Candida auris
• Strategies to prevent AR infections
![Page 5: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/5.jpg)
Disclaimers
• I am not a clinical microbiologist• It took me 3 years to learn this stuff, so we won’t cover everything in an hour
![Page 6: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/6.jpg)
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. 2013
![Page 7: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/7.jpg)
Factors Contributing to Spread in Hospitals
• Patient Factors:– Severity of illness– Immunocompromising conditions– Medical technology and procedures (LDA, open wounds)
• Infection Control:– Increased introduction of resistant organisms from the community (and residential facilities)– Ineffective infection control & isolation practices (esp. compliance)
• Antibiotic Overuse:– Increased use of antimicrobial prophylaxis– Increased use of polymicrobial antimicrobial therapy– High antimicrobial use in intensive care units
Source: Shlaes D, et al. Clin Infect Dis 1997;25:684‐99.
![Page 8: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/8.jpg)
IDSA. Bad Bugs No Drugs. 2004
![Page 9: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/9.jpg)
![Page 10: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/10.jpg)
Why is this so fast?
• Most antibiotics are microbe‐derived products– Penicillin: Penicillium– Cephalosporins: Acremonium– Carbapenems: Streptomyces cattleya– Vancomycin: Amycolatopsis orientalis– Also: tetracyclines, polymyxins, amphotericin B…
• Microbes have been fighting this war for billions of years– The genes for resistance are in the genetic pool
![Page 11: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/11.jpg)
Principles of Antibiotic Resistance(Levy SB. NEJM, 1998)
1. Given sufficient time and drug use, antibiotic resistance will emerge2. Resistance is progressive, evolving from low levels through intermediate
to high levels3. Organisms resistant to one antibiotic are likely to become resistant to
other antibiotics4. Once resistance appears, it is likely to decline slowly, if at all5. The use of antibiotics by any one person affects others in the extended
as well as the immediate environment
![Page 12: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/12.jpg)
![Page 13: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/13.jpg)
Farm‐to‐TableHospital
![Page 14: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/14.jpg)
Modern Care Continuum
Hospital
HomeSkilled Nursing
• Patients may cycle between inpatient facilities, skilled nursing facilities, and home
• AR pathogens can be acquired at any site and carried to the others
• Inadequate infection control and poor antibiotic stewardship at any one site can create problems at the others.
![Page 15: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/15.jpg)
CDC Four Core Activities to Fight Resistance
1. Prevent infections, prevent spread of resistance2. Tracking3. Improving antibiotic prescribing/stewardship4. Developing new drugs and diagnostic tests
![Page 16: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/16.jpg)
Antibiotic Pipeline
• Only 9 antibiotics approved since 2010• Currently ~40 new antibiotics in development
– Historically, about 1 in 5 will reach the market
• Barrier: limitations on sales– AR pathogens still uncommon– Brief courses– Antimicrobial stewardship
• Policy fixes: extension of patent protection, lower bar for FDA approval
![Page 17: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/17.jpg)
Antibiotics Approved Since 2010
2010 2011 2012 2013 2014 2015
Ceftaroline Telavancin Tedizolid
CeftolozaneTazobactam
Oritavancin
Dalbavancin
Ceftazidime/Avibactam
2016 2017
Meropenem/Vaborbactam
Delafloxacin
![Page 18: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/18.jpg)
Emerging AR Pathogens of Importance in US Inpatient Settings
• Enterococcus:– Ampicillin, vancomycin
• Staphyloccus aureus:– Oxacillin, clindamycin, vancomycin?
• Gram‐negative enterics: – ESBL, CRE
• Pseudomonas, Stenotrophomonas, Acinetobacter• Fungi:
– Candida krusei, C. auris
![Page 19: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/19.jpg)
ESKAPE Pathogens
Enterococcus faecium (VRE)
Staphylococcus aureus (MRSA)
Klebsiella and Escherichia coli producing ESBL
Acinetobacter baumannii
Pseudomonas aeruginosa
Enterobacteriaceace
![Page 20: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/20.jpg)
Diagnosis of AR PathogensCulture• “Gold standard”• Requires sampling of site of infection prior to therapy
• Allows determination of antimicrobial susceptibility
PCR• From blood, still requires an incubation step
• Rapid species identification• Blood culture systems rapidly detect some resistance mechanisms (e.g., VRE, MRSA), but not 100%
• Direct detection of bacteria (e.g., from CSF or stool) can NOT provide resistance information
![Page 21: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/21.jpg)
Mean Inhibitory Concentration (MIC)
• The MIC is a phenotypic test of a bacterial isolate’s growth when exposed to a particular antibiotic
• The lowest concentration of the antibiotic needed to prevent the bacteria from growing– Expressed in mcg/mL
• Requires interpretation!!– Cannot just pick the lowest MIC from the Micro report
![Page 22: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/22.jpg)
MIC Determination – Broth Microdilution
4.0µg/mL
4.0µg/mL
0.25µg/mL
0.5µg/mL
1.0µg/mL
2.0µg/mL
8.0µg/mL
16µg/mL
Known quantity of bacteria placed into each tube
Increasing antibiotic concentration
Lowest concentration of an antimicrobial that results in the inhibition of visible
growth of a microorganism
Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 2000;123(1 Pt 2):S1.
Many Labs Use Automated Testing
![Page 23: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/23.jpg)
MIC Determination – Kirby‐Bauer
1. Add test bacteria to small amount of melted agar.2. Pour over surface of nutrient agar plate, let gel.3. Add paper disks with known dose of antibiotic to surface. 4. Incubate: antibiotic will diffuse into medium as cells grow.5. Examine plate: look for clear zones around disk where growth is inhibited.6. Measure diameter of clear zones.7. Diameter determines S/I/R
Susceptible
![Page 24: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/24.jpg)
MIC Determination – E‐test
E-test®
• E‐test strip impregnated with a known gradient of antibiotic
• Where the clearance zone intersects with the strip MIC
![Page 25: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/25.jpg)
MIC Interpretation• For EVERY (relevant) combination of species and antibiotic, there is a breakpoint established by CLSI
• Requires understanding of pharmacology of antibiotic• The breakpoint allows interpretation as susceptibleor resistant
– For example: MIC=1, breakpoint=4 susceptible
• Not all breakpoints are appropriate. – S. aureus vancomycin breakpoint is <=2. However, outcomes are worse if MIC=2 than if MIC<=1.
![Page 26: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/26.jpg)
Modes of Antibiotic Therapy
Empiric– Infection suspected – Pathogen not yet known (may never be found)
– Cover most common possibilities
– Broad, multiple agents, more toxicity
Directed– Infection proven, pathogen identified, susceptibility known or predicted
– Almost always single‐agent– As narrow as possible– Almost always less toxic
![Page 27: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/27.jpg)
Gram‐positive AR Pathogens
![Page 28: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/28.jpg)
Staphylococcus aureus
• Community and nosocomial• Infection types:
– Skin and soft‐tissue– Bone/joint– Nosocomial and postviralpneumonia
– Wound infections– Bacteremia, CRBSI– Endocarditis/endovascular– Metastatic infection
![Page 29: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/29.jpg)
Staphylococcus aureus
• Plain MSSA can be killed by most beta‐lactams (nafcillin, oxacillin, cefazolin…)– MSSA may be just as invasive/virulent as MRSA
• Methicillin resistance is common– mecA gene alters the beta‐lactam target (can detect by PCR)– Treatment: usually vancomycin– Options (severe infxn): daptomycin, ceftaroline– Options (less severe): linezolid, clindamycin, doxycycline, TMP‐SMX
![Page 30: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/30.jpg)
Staphylococcus aureus
• Clindamycin resistance– Clindamycin was an effective workaround for MRSA (not bacteremia), but regions are seeing variable rates of resistance
• Vancomycin resistance (VISA and VRSA)– Extremely rare (handful of cases of VRSA ever)– However, “MIC creep” is a well‐described phenomenon in hospitals with heavy vancomycin use – the most common MIC may rise from 0.5 1 1.5 2
![Page 31: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/31.jpg)
Healthcare‐ vs. Community‐Acquired MRSA
• HA‐MRSA emerged in the 1960s– Resistant to more antibiotics– Generally less virulent
• CA‐MRSA (USA300 strain) emerged in the early 2000s– Highly virulent, propensity to cause SSTI
• CA‐MRSA strains have moved into healthcare settings– Less distinction between the two
![Page 32: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/32.jpg)
Staphylococcus aureus ‐ Summary• Causes a LOT of infections
– Nosocomial and community‐acquired
• Highly virulent• We have options for dealing with MRSA
– But usually more toxic and/or less effective than beta‐lactams– The threat of MRSA near‐universal use of empiric vancomycin in severe acute infections
– Can screen and isolate and decolonize patients
• VISA/VRSA are rare but can gradually be uncovered
![Page 33: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/33.jpg)
Enterococcus faecium
• Infections:– UTI– CRBSI– Endocarditis– Wounds
• Less virulent than S. aureus, but difficult to treat
Vancomycin resistance ~75%
![Page 34: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/34.jpg)
Enterococcus faecium• Generally, enterococci are susceptible to ampicillin but not cephalosporins– Tend to be hard to kill and synergistic approaches are used
• E. faecium is nearly universally resistant to ampicillin and usually resistant to vancomycin (VRE)
• Rarely encountered outside of healthcare settings– Major nosocomial AR pathogen
• High‐risk populations (neonates, immunocompromised) can be screened with perirectal swabs
![Page 35: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/35.jpg)
Treatment of VRE
• Vancomycin resistance encoded by genes vanA or vanB– Change in structure of target complete resistance
• Daptomycin is often active• Linezolid is almost always active• Others: tigecycline, quinupristin‐dalfopristin, telavancin
![Page 36: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/36.jpg)
Gram‐negative AR Pathogens
![Page 37: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/37.jpg)
Gram‐negative vs Gram‐positive
• Both have a cell wall• Gram‐negatives have an outer membrane
• Able to regulate what comes in and out much more complex
Cell wall
![Page 38: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/38.jpg)
Gram‐negative Rods – General Principles
• Genotype may not predict phenotype• Lab phenotype may not predict clinical phenotype• Different mechanisms interact (e.g., moderate expression of a beta‐lactamase plus an efflux pump may act synergistically)
• Gram‐negatives may share plasmid DNA promiscuously
![Page 39: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/39.jpg)
Extended‐Spectrum Beta‐lactamases (ESBL)
• Large heterogeneous family of enzymes• “Extended spectrum” generally means activity against penicillins, cephalosporins (including 4th‐gen), and aztreonam
• Labs may use 3rd‐gen cephalosporin resistance as proxy• NOT active against carbapenems• Inhibited by beta‐lactamase inhibitors (e.g., tazobactam)
![Page 40: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/40.jpg)
Epidemiology of ESBL
• Frequently found in:– Klebsiella pneumoniae and oxytoca, E. coli
• Less commonly: Acinetobacter, Burkholderia, Citrobacter, Enterobacter, Morganella, Pseudomonas, Salmonella, Serratia, Shigella
• Plasmid‐based, mobile• In general, one single type tends to predominate in a region or hospital
![Page 41: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/41.jpg)
ESBL – Clinical Strategies
• Often resistant to other antibiotic classes as well (aminoglycosides and fluoroquinolones)
• Beta‐lactam strategies– Carbapenems have given the best outcomes– Avoid cephalosporins (even if reported susceptible)– Pip‐tazo has been associated with treatment failures. Fine for urine.
![Page 42: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/42.jpg)
Carbapenem Resistance• Carbapenems are the last‐line beta‐lactams• The future of Gram‐negative infections• In Enterobacteriaceae (e.g., E. coli, Klebsiella, Enterobacter), carbapenem resistance is mediated by carbapenemases– CRE = Carbapenem‐resistant Enterobacteriaceae
• Pseudomonasmay have other mechanisms, such as altered porins and efflux pumps
![Page 43: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/43.jpg)
Carbapenemases
• Major infection control concern• Most are plasmid‐mediated• In general, active against all beta‐lactams• Generally not inhibited by BLIs• Examples:
– KPC = Klebsiella pneumoniae carbapenemase– NDM = New Delhi metallo‐beta‐lactamase
![Page 44: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/44.jpg)
![Page 45: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/45.jpg)
Treatment• Often have resistance to other classes• Other options
– Tigecycline (bad for bloodstream infections and pneumonia)– Polymyxins: colistin, polymyxin B (extraordinarily toxic)
• Some suggest combination therapy when possible: a polymyxin plus tigecycline +/‐ carbapenem; polymyxin plus carbapenem or rifampin, etc.
• Newer antibiotics (ceftazidime‐avibactam, meropenem‐vaborbactam) may be effective and much less toxic.
![Page 46: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/46.jpg)
Polymyxin Resistance• Colistin and Polymyxin B: last‐line antibiotics for resistant Gram‐negative infections– Abandoned in the 1970s due to toxicity, revived in 2000s
• Resistance is mediated by mcr genes– Plasmid‐mediated (transmissible)
• Emerged in food animals in China in 2014– Now spread across the globe
• Colistin is commonly used in agriculture, especially in China
![Page 47: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/47.jpg)
![Page 48: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/48.jpg)
Pseudomonas aeruginosa• Important cause of VAP (20 percent), CLABSI (18 percent), CAUTI, SSI
• Can accumulate multiple mechanisms of resistance– Often mediated at the outer membrane: porins and efflux pumps
• If Pseudomonas is suspected, consider double‐coverage for empiric therapy: e.g., add tobramycin to cefepime to cover cefepime‐resistant isolates
• Double‐coverage is generally not recommended for targetedtherapy
![Page 49: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/49.jpg)
Acinetobacter baumanii• Important nosocomial bacterial pathogen: VAP (8.4 percent), CLABSI, CAUTI, SSI
• Intrinsically resistant to many agents• Definitions:
– MDR: non‐susceptible >= 1 agent in >= 3 categories (9 total)– XDR: non‐susceptible to >= 1 agent all but <=2 categories– PDR: non‐susceptible to all possibly active drugs
• Resistant infections treated with polymyxins + tigecycline or minocycline
![Page 50: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/50.jpg)
Prevention of Resistant Gram‐negative infections
• High‐risk populations:– Trauma, diabetes, malignancy, organ transplantation– Mechanical ventilation, indwelling Foley, CVCs– Poor functional status, severe illness
• Strategies– Antibiotic stewardship– Contact precautions– During CRE outbreaks, screening for rectal colonization may be a good approach
![Page 51: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/51.jpg)
Antifungal‐Resistant Candida
![Page 52: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/52.jpg)
Invasive Candidiasis• Risk factors
– Trauma, burns– Extremes of age– Venous catheter– TPN– Broad‐spectrum antibiotic exposure– Renal failure– Abdominal surgery, GI tract perforations– Immunocompromise
![Page 53: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/53.jpg)
Antifungal Agents
1. Triazoles– Fluconazole – fairly safe, effective against most Candida– Voriconazole – slightly broader‐spectrum against Candida, lots of toxicities and challenging PK
2. Echinocandins (micafungin, caspofungin, anidulafungin)– Very broad coverage of virtually all Candida. Minimal toxicity.
3. Amphotericin B– Very broad coverage. Very toxic.
![Page 54: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/54.jpg)
Antifungal Resistance• C. albicans is usually fully susceptible
– Historically the most common cause of infection, but non‐albicansare becoming more common
• Examples– C. krusei is intrinsically resistant to fluconazole– C. lusitaniae is usually resistant to amphotericin B– C. glabrata is often resistant to azoles
• Echinocandin (micafungin, caspofungin) resistance is increasingly seen
![Page 55: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/55.jpg)
Candida auris
• Emerging Candida species– 153 cases in 10 states
• Important concern for Infection Prevention– Prolonged patient colonization– Prolonged survival on surfaces
• Frequently misidentified by automated lab systems
![Page 56: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/56.jpg)
Candida auris ‐ Significance
• Infections have tended to be severe• Antifungal resistance
– Most are resistant to fluconazole/voriconazole– 30% are resistant to amphotericin B– 5 cases of echinocandin resistance. Can develop on therapy.– Specter of pan‐resistant Candida
![Page 57: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/57.jpg)
Candida auris
Centers for Disease Control and Prevention
![Page 58: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/58.jpg)
Candida auris
Centers for Disease Control and Prevention
![Page 59: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/59.jpg)
Infection Control for Candida auris
• CDC requests immediate reporting ([email protected])• Single‐patient room, contact precautions• Screen index patient’s contacts for colonization• Disinfection: disinfectants effective against C‐diff spores
![Page 60: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/60.jpg)
Dealing with Resistant Pathogens
Community• Provide recommended
vaccines• Avoid unnecessary antibiotics• Use appropriate drug to cover
antibiotic resistant pathogens• Provide appropriate dose and
duration• Use short course therapy if
validated
Hospital• Provide recommended vaccines• Avoid unnecessary antibiotics• Practice appropriate infection control• Avoid prophylactic therapy unless
supported by scientific evidence• Use appropriate drug to cover
antibiotic resistant pathogens• Provide appropriate dose and duration• Use short course therapy if validated• Practice de‐escalation
![Page 61: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/61.jpg)
Acknowledgements
• Jon Juliano provided his slides from last year• Dr. Weber for inviting me• Amy Powell for organizing
![Page 62: Management of Antibiotic Resistant Pathogensspice.unc.edu/wp-content/uploads/2017/05/10-Management... · 2018-07-05 · Overview • Introduction – Burden of antibiotic resistance](https://reader036.vdocuments.us/reader036/viewer/2022070902/5f52c18f5d84366af72d23b0/html5/thumbnails/62.jpg)
References• ResistanceMap ‐ Antibiotic Resistance. https://resistancemap.cddep.org/. Accessed October 21,
2017.• Antibiotic Resistance Threats in the United States, 2013 | Antibiotic/Antimicrobial Resistance | CDC.
https://www.cdc.gov/drugresistance/threat‐report‐2013/index.html. Accessed October 21, 2017.• Pew Charitable Trusts. Antibiotics Currently in Clinical Development. http://bit.ly/1qbnVZ0. Accessed
October 21, 2017.• Fischer M, Long SS Prober CG. Principles and Practice of Pediatric Infectious Diseases [Electronic
Resource]. Fifth edition. Philadelphia, PA: Elsevier; 2018.• Candida auris Clinical Update ‐ September 2,017 | Fungal Diseases | CDC.
https://www.cdc.gov/fungal/diseases/candidiasis/c‐auris‐alert‐09‐17.html. Published September 27, 2017. Accessed October 21, 2017.
• Bennett J, Blaser MJ, Dolin R. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases [Electronic Resource]. Updated Eighth Edition. Philadelphia, PA: Elsevier/Saunders; 2015.